Does your Anti-SARS-CoV-2 assay detect antibodies formed after vaccination?
And will your Anti-SARS-CoV-2 assay allow quantitative detection of antibody concentration to evaluate vaccination success?
[Feb 18, 2021]
To support the IvD & Pharma Industry in their efforts against the COVID-19 pandemic, unique SARS-CoV-2 immunity seroconversion panels are now being developed by Biomex GmbH, Germany.
These post vaccination panels consist of a collection of donors immunized with either BioNTech/Pfizer or Moderna vaccine.
Biomex is currently collecting the following sample set:
◊ The existing panel consists of 16 donations from 50 donors containing
1 mL of serum from each member.
◊ The collection period expands over 8 weeks with 2 donations per week.
Accordingly, this seroconversion panel will have a total size of
800 serum samples.
◊ The first collections have started at the first vaccination.
You can receive the vaccination panel at the end of the collection or as partial shipments.